Aclaris Therapeutics Inc’s filing revealed that its Director Mehra Anand acquired Company’s shares for reported $1.5 million on Nov 19 ’24. In the deal valued at $2.25 per share,666,666 shares were bought. As a result of this transaction, Mehra Anand now holds 710,030 shares worth roughly $0.92 million.
Then, Leonard Braden Michael bought 206,025 shares, generating $256,357 in total proceeds. Upon buying the shares at $1.24, the 10% Owner now owns 14,250,000 shares.
Before that, Leonard Braden Michael bought 167,544 shares. Aclaris Therapeutics Inc shares valued at $216,400 were divested by the 10% Owner at a price of $1.29 per share. As a result of the transaction, Leonard Braden Michael now holds 14,043,975 shares, worth roughly $18.26 million.
A number of analysts have revised their coverage, including H.C. Wainwright’s analysts, who increased its forecast for the stock in late December from “a Neutral” to “a Buy”. Cantor Fitzgerald also remained covering ACRS and has increased its forecast on November 20, 2024 with a “an Overweight” recommendation from previously “Neutral” rating. Leerink Partners revised its rating on November 19, 2024. It rated ACRS as “an Outperform” which previously was an “a Market perform”.
Price Performance Review of ACRS
On Monday, Aclaris Therapeutics Inc [NASDAQ:ACRS] saw its stock fall -0.76% to $1.30. Over the last five days, the stock has gained 4.00%. Aclaris Therapeutics Inc shares have fallen nearly -47.58% since the year began. Nevertheless, the stocks have risen 10.17% over the past one year. While a 52-week high of $5.17 was reached on 01/03/25, a 52-week low of $0.95 was recorded on 04/10/25.
How much short interest is there in Aclaris Therapeutics Inc?
A steep rise in short interest was recorded in Aclaris Therapeutics Inc stocks on 2025-04-30, dropping by -1.8 million shares to a total of 4.45 million shares. Yahoo Finance data shows the prior-month short interest on 2025-03-31 was 6.24 million shares. There was a decline of -40.43%, which implies that there is a negative sentiment for the stock.
